A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination
with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus
(HCV)-infected participants who are treatment-naive or treatment-experienced (prior relapser
or non-responder to Interferon-based therapy) in Japan.